Recommended

Read our new eBook on a new means to perform single-cell functional analysis.
New Webinar: Neurological disorders – organoids for early drug discovery
Listen to our latest podcast: breaking resistance – the future of immunotherapy in oncology
Download now: The latest research, insights and developments in vaccines
Register now: Ion Channel Drug Discovery – Recent Advances in Novel Non-Opioid Pain Research
Register now: SAFIRE: AI predicted ADME for drug discovery: leveraging bioprint
Infographic

Infographic: Targeted protein degradation

In this infographic, we discuss both inhibition and degradation, the advantages and challenges related to each approach and the key points you need to consider when designing your protein degraders.

Researchers are using targeted protein degradation as a strategy to develop drugs that target disease-causing proteins where traditional inhibitor drugs can’t be used. 

In an effort to expand the druggable space, researchers are developing novel therapeutic strategies that target challenging disease-causing proteins. In the last decade, targeted protein degradation (TPD) is getting a lot of attention as a new and promising modality to treat a variety of diseases from cancer to Alzheimer’s. By taking proteins down the cell’s own degradation pathway instead of the typical inhibition approach, TPD allows researchers to develop successful therapies that address previously undruggable targets due to the absence of defined binding sites.